Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Silverarc Capital Management LLC

Silverarc Capital Management LLC lifted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 116.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,395 shares of the company's stock after acquiring an additional 81,879 shares during the period. Silverarc Capital Management LLC owned approximately 0.27% of Structure Therapeutics worth $4,133,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd lifted its stake in shares of Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its position in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $40,000. Assetmark Inc. boosted its holdings in Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after acquiring an additional 953 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Structure Therapeutics by 673.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after acquiring an additional 3,549 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GPCR shares. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $81.29.

Structure Therapeutics Trading Up 0.4 %

NASDAQ GPCR traded up $0.09 on Friday, hitting $23.74. 731,787 shares of the stock traded hands, compared to its average volume of 913,703. The company has a market capitalization of $1.36 billion, a P/E ratio of -32.08 and a beta of -1.35. The stock has a 50-day moving average of $20.17 and a 200 day moving average of $27.78. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.